7IJH
 
 | |
7IJI
 | |
7IJJ
 | |
7IJK
 | |
7IJL
 | |
7IJM
 | |
9PYS
 | | NMR RDC refinement of the helical domain of the SARS-CoV-2 monomeric Main Protease (MPROH41Q,10-306) | | Descriptor: | 3C-like proteinase nsp5 | | Authors: | Smith, M.J, Ying, J, Shen, Y, Louis, J.M, Bax, A. | | Deposit date: | 2025-08-08 | | Release date: | 2025-09-17 | | Method: | SOLUTION NMR | | Cite: | Solution Domain Dynamics of Monomeric SARS-CoV-2 Main Protease Revealed by Optimized NMR Residual Dipolar Coupling Measurements.
To Be Published
|
|
9PYT
 | | NMR RDC refinement of the catalytic domain of the SARS-CoV-2 monomeric Main Protease (MPROH41Q,10-306) | | Descriptor: | 3C-like proteinase nsp5 | | Authors: | Smith, M.J, Ying, J, Shen, Y, Louis, J.M, Bax, A. | | Deposit date: | 2025-08-08 | | Release date: | 2025-09-17 | | Method: | SOLUTION NMR | | Cite: | Solution Domain Dynamics of Monomeric SARS-CoV-2 Main Pro-tease Revealed by Optimized NMR Residual Dipolar Coupling Measurements.
To Be Published
|
|
9PYW
 | |
9PYZ
 | |
9PZ0
 | |
9WHE
 | | A novel, covalent and highly synthetically accessible SARS-CoV-2 Mpro chloroacetamide inhibitor | | Descriptor: | (2~{R})-~{N}-[4,4-bis(fluoranyl)cyclohexyl]-2-[ethanoyl-[4-(1,2-thiazol-5-yl)phenyl]amino]-2-pyrazin-2-yl-ethanamide, 1,2-ETHANEDIOL, 3C-like proteinase, ... | | Authors: | Zagribelnyy, B, Zhavoronkov, A. | | Deposit date: | 2025-08-26 | | Release date: | 2025-09-17 | | Last modified: | 2025-10-15 | | Method: | X-RAY DIFFRACTION (1.82 Å) | | Cite: | A novel, covalent and highly synthetically accessible SARS-CoV-2 Mpro chloroacetamide inhibitor
To Be Published
|
|
9MDQ
 | | Crystal Structure of SARS-CoV-2 Omicron Main Protease (Mpro) Complex with Azapeptide Inhibitor 20a | | Descriptor: | 3C-like proteinase nsp5, N-[(2S)-1-{2-(dichloroacetyl)-2-[(2-oxo-1,2-dihydropyridin-3-yl)methyl]hydrazin-1-yl}-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide | | Authors: | Vishwakarma, J, Taylor, A.B, Harris, R.S. | | Deposit date: | 2024-12-05 | | Release date: | 2025-09-24 | | Last modified: | 2025-10-08 | | Method: | X-RAY DIFFRACTION (1.6 Å) | | Cite: | Azapeptide-Based SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Enzyme Inhibition, Structural Determination, and Antiviral Activity.
J.Med.Chem., 68, 2025
|
|
9Q1J
 | | Cryo-EM structure of SARS-CoV-2 nsp10-nsp14 E191A mutant-T20P14-R complex | | Descriptor: | MAGNESIUM ION, Non-structural protein 10, Proofreading exoribonuclease, ... | | Authors: | Yang, Y, Liu, C, Liu, B. | | Deposit date: | 2025-08-14 | | Release date: | 2025-09-24 | | Last modified: | 2025-10-15 | | Method: | ELECTRON MICROSCOPY (2.81 Å) | | Cite: | Molecular basis of SARS-CoV-2 proofreading enzyme-mediated resistance to remdesivir.
Proc.Natl.Acad.Sci.USA, 122, 2025
|
|
9VS1
 | | Crystal structure of SARS-CoV-2 3CL protease in complex with compound 15 | | Descriptor: | 1,2-ETHANEDIOL, 3C-like proteinase, 4-chloranyl-3-[6-methyl-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-2,4,5-tris(oxidanylidene)-1-[[3,4,5-tris(fluoranyl)phenyl]methyl]pyrido[4,3-d]pyrimidin-7-yl]benzenecarbonitrile | | Authors: | Yamamoto, S, Taoda, Y. | | Deposit date: | 2025-07-08 | | Release date: | 2025-09-24 | | Method: | X-RAY DIFFRACTION (1.7 Å) | | Cite: | Design, synthesis and biological evaluation of novel quinazolinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors.
Bioorg.Med.Chem.Lett., 129, 2025
|
|
8YUB
 | | Crystal structure of SARS-CoV-2 ConSp RBD in complex with neutralizing antibody CC25.4 Fab | | Descriptor: | 1,2-ETHANEDIOL, Neutralizing antibody CC25.4 heavy chain, Neutralizing antibody CC25.4 light chain, ... | | Authors: | Kang, J.M, Yuan, M, Han, B.W, Wilson, I.A. | | Deposit date: | 2024-03-27 | | Release date: | 2025-10-01 | | Method: | X-RAY DIFFRACTION (2.49 Å) | | Cite: | Structure and antigenic characteristics of consensus sequence-based SARS-CoV-2 antigen
To Be Published
|
|
8YUC
 | | Crystal structure of SARS-CoV-2 ConSp RBD in complex with antibodies PDI222 Fab and COVA1-16 Fab | | Descriptor: | COVA1-16 heavy chain, COVA1-16 light chain, PDI222 heavy chain, ... | | Authors: | Kang, J.M, Yuan, M, Han, B.W, Wilson, I.A. | | Deposit date: | 2024-03-27 | | Release date: | 2025-10-01 | | Method: | X-RAY DIFFRACTION (4.51 Å) | | Cite: | Structure and antigenic characteristics of consensus sequence-based SARS-CoV-2 antigen
To Be Published
|
|
9BF7
 | | SARS-CoV-2 Papain-like Protease (PLpro) C111S Untagged Crystal Structure | | Descriptor: | ACETATE ION, GLYCEROL, PHOSPHATE ION, ... | | Authors: | Al-Homoudi, A.I, Brunzelle, J.S, Gavande, N, Kovari, L.C. | | Deposit date: | 2024-04-17 | | Release date: | 2025-10-01 | | Last modified: | 2025-10-15 | | Method: | X-RAY DIFFRACTION (1.68 Å) | | Cite: | Human Structural Homologues of SARS-CoV-2 PL pro as Anti-Targets: A Strategic Panel Analysis.
MicroPubl Biol, 2025, 2025
|
|
9OG4
 | | SARS-COV-2-6P-MUT7 S PROTEIN-DY-III-281 complex closed conformation | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein, ... | | Authors: | Chandravanshi, M, Niu, L, Tolbert, W.D, Pazgier, M. | | Deposit date: | 2025-04-30 | | Release date: | 2025-10-01 | | Method: | ELECTRON MICROSCOPY (3.56 Å) | | Cite: | Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants
J.Virol., 2025
|
|
9OG5
 | | SARS-COV-2-6P-MUT7 S PROTEIN-DY-III-281 complex 1 RBD up conformation | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein, ... | | Authors: | Chandravanshi, M, Niu, L, Tolbert, W.D, Pazgier, M. | | Deposit date: | 2025-04-30 | | Release date: | 2025-10-01 | | Method: | ELECTRON MICROSCOPY (3.3 Å) | | Cite: | Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants
J.Virol., 2025
|
|
9OG6
 | | Apo SARS-COV-2-6P-MUT7 S PROTEIN closed conformation | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein, ... | | Authors: | Niu, L, Chandravanshi, M, Tolbert, W.D, Pazgier, M. | | Deposit date: | 2025-04-30 | | Release date: | 2025-10-01 | | Method: | ELECTRON MICROSCOPY (3.14 Å) | | Cite: | Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants
J.Virol., 2025
|
|
9OG7
 | | APO SARS-COV-2-6P-MUT7 S PROTEIN 1 RBD UP CONFORMATION | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein, ... | | Authors: | Niu, L, Chandravanshi, M, Tolbert, W.D, Pazgier, M. | | Deposit date: | 2025-04-30 | | Release date: | 2025-10-01 | | Method: | ELECTRON MICROSCOPY (3.09 Å) | | Cite: | Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants
J.Virol., 2025
|
|
9SAO
 | |
9SAP
 | |
9SAQ
 | |
